4.0
4. Feb. 2023
Aktueller Mitarbeiter, mehr als 8 Jahre
Whippany, NJ
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
Amazing people, good work life balance, amazing benefits, unsurpassed retirement benefits.
Kontras
Pharma performance dragged down by Xarelto and Eyelea going off patent, coupled with Monsanto lawsuits depressing the stock, your LTI and STI barely hit the target. Salary is barely median within industry, yet HR takes the stance it's competitive. Oncology pipeline has dried up, new management not able to make a decision on acquisitions to save their life and their entire pipeline commercialization team has been dissolved (their BD&L team is led by a confused lady, at best). They are hanging by a Nubeqa thread that has a peak potential of 4bn, yet Bayer has 100bn of debt on the books. So get promoted and move up, then move on.